OCGN This is nice move from Ocugen. Ocular Therapy is good market. See REGN, what they did in last years. Gene Therapy might be risky research, but it looks good sofar. Under the future agreement, Ocugen said it will receive up to $11 million in upfront and near-term milestone payments, plus $1 million in sales milestones for every $15 million in Korean sales.
